the ipilimumab dose was reduced to 0.7 mg/kg for the other 3 cohorts, which enabled a sitravatinib dose escalation up to 100 mg daily. Overall, the objective response rate (ORR) was 45.5%, and the ...

LOUISVILLE, Ky. -- More than half of patients with newly diagnosed metastatic kidney cancer responded to a novel drug ...

Scientists at Anand Agricultural University (AAU) in Gujarat, India, have developed a new banana variety called Anand Vaaman.

WALTHAM, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for ...

Givastomig data presented at ESMO 2024 and SITC 2024 highlights encouraging monotherapy data On track to dose first patient ...

Berghoff and colleagues said the results of the therapy were significant. “In the prevention experiment, treatment with 6.25 ...

Analyst Andrew Fein from H.C. Wainwright maintained a Buy rating on Dyne Therapeutics (DYN – Research Report) and keeping the price ...

Givastomig data presented at ESMO 2024 and SITC 2024 highlights encouraging monotherapy data On track to dose first patient in randomized Phase 2 study of uliledlimab ...

Department of Physiology, Harold Hamm Diabetes Center, The University of Oklahoma Health Science Center, Oklahoma City, United States ...

We have seen a number of dynamic changes in MDS over the last few years, and integrating them into our treatment paradigm will impact our approach, and perhaps offer a glimpse into the future." ...

Revenue: Total revenue was $2.1 million for the quarter ended September 30, 2024, comprised of $0.6 million in net product revenue for neffy sales, which reflects revenues from only one week following ...

A central question in adult stem cell biology is elucidating the signaling pathways regulating their dynamics and function in diverse physiological and age-related contexts. Muscle stem cells in ...